Yunxin Chen
Overview
Explore the profile of Yunxin Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
897
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Tan M, Chen Y, Smith E
Blood Adv
. 2024 Jun;
8(16):4433-4446.
PMID: 38865708
The identification and targeting of B-cell maturation antigen (BCMA) through immunotherapeutic strategies such as antibody-drug conjugates, chimeric antigen receptor T cells, and T-cell engagers have revolutionized the care of patients...
12.
Xu X, Chen Y, Liu P, Luo H, Li Z, Li D, et al.
Nat Commun
. 2024 May;
15(1):4368.
PMID: 38778090
Two-dimensional (2D) AMX compounds are a family of mixed ionic and electronic conductors (where A is a monovalent metal ion, M is a trivalent metal, and X is a chalcogen)...
13.
Tan C, Tan M, Nagarajan C, Chng W, Chee Y, Ooi M, et al.
JCO Oncol Pract
. 2023 Oct;
19(12):1168-1178.
PMID: 37844267
Purpose: Treatment options for myeloma and indolent lymphoma are increasing exponentially, with distinct efficacy, side effects, and cost. We aim to determine the factors influencing patient and caregiver treatment preferences....
14.
Guo T, Pan K, Chen Y, Tian Y, Deng J, Li J
Sci Total Environ
. 2023 Oct;
907:167792.
PMID: 37838059
The evolution of emerging contaminants (ECs) has caused greater requirements and challenges to the current biological wastewater treatment technology. As one of the most promising biological treatment technologies, the aerobic...
15.
Teo W, Ong I, Tong J, Ong W, Lin A, Song F, et al.
Curr Hematol Malig Rep
. 2023 Jul;
18(5):190-200.
PMID: 37400631
Purpose Of Review: The development of potent novel agents has improved outcomes for patients with multiple myeloma (MM). Heterogeneity of response to therapy, an expanding arsenal of treatment options, and...
16.
Huang X, Gan G, Chan E, Heng K, Perumal S, Salleh R, et al.
Haematologica
. 2023 May;
108(11):3131-3134.
PMID: 37165850
No abstract available.
17.
Ong S, Chen Y, Tan M, Ho A, Hwang W, Lim F
Eur J Haematol
. 2023 Mar;
112(2):144-152.
PMID: 36987995
Although chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable efficacy in patients with chemo-refractory B-cell lymphoma, a significant portion is refractory or relapse. Resistance is a major barrier to...
18.
Guo X, Chen Y, Liu M, Zhang S, Zhong C, Chen A, et al.
Endoscopy
. 2023 Feb;
55(S 01):E400-E401.
PMID: 36736362
No abstract available.
19.
Tan J, Wee L, Tan Y, Conceicao E, Lim F, Chen Y, et al.
Transpl Infect Dis
. 2023 Jan;
25(3):e14024.
PMID: 36715661
Introduction: A high incidence of mortality and severe COVID-19 infection was reported in hematopoietic stem cell transplant (HSCT) recipients during the early phases of the COVID-19 pandemic; however, outcomes with...
20.
Ng L, Tham C, Lim F, Chen Y, Ong S, Nagarajan C, et al.
Blood Cell Ther
. 2023 Jan;
4(4):92-100.
PMID: 36714065
Aggressive T and NK/T-cell lymphoma are known to have a high risk of relapse and poor long-term prognosis. Hematopoietic stem cell transplantation has been performed as part of consolidation or...